Oryzon Genomics S.A.
ORYZF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $4 | $0 | $7 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $4 | $0 | $7 |
| % Margin | – | 96.5% | – | 95.9% |
| R&D Expenses | $4 | $1 | $2 | $1 |
| G&A Expenses | $1 | $1 | $1 | $3 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$2 |
| Other Operating Expenses | $0 | $5 | $0 | $0 |
| Operating Expenses | $5 | $7 | $3 | $2 |
| Operating Income | -$5 | -$3 | -$3 | $5 |
| % Margin | – | -69.5% | – | 72.8% |
| Other Income/Exp. Net | $5 | $2 | $2 | -$8 |
| Pre-Tax Income | $0 | -$1 | -$2 | -$3 |
| Tax Expense | $0 | -$1 | $0 | -$2 |
| Net Income | $0 | -$0 | -$2 | -$1 |
| % Margin | – | -0.7% | – | -16.4% |
| EPS | 0.01 | -0 | -0.026 | -0.018 |
| % Growth | 2,600% | 98.5% | -49.7% | – |
| EPS Diluted | 0.01 | -0 | -0.026 | -0.018 |
| Weighted Avg Shares Out | 75 | 78 | 65 | 64 |
| Weighted Avg Shares Out Dil | 75 | 78 | 65 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | $0 | -$3 | $5 |
| % Margin | – | 7% | – | 72.2% |